This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Acadia Healthcare (ACHC) Q4 Earnings Beat on Strong Admissions
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q4 results gain on strong growth in revenue per patient day. It expects adjusted EPS of $3.40-$3.70 for 2024, the mid-point of which implies a 3.2% rise from the 2023 reported figure.
Acadia Healthcare (ACHC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 6.25% and 1.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?
by Zacks Equity Research
Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.
Community Health Systems (CYH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of -1,466.67% and 0.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
by Zacks Equity Research
InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.
CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.
Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging
by Zacks Equity Research
Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.
Strength Seen in Tenet (THC): Can Its 7.7% Jump Turn into More Strength?
by Zacks Equity Research
Tenet (THC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women
by Zacks Equity Research
LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.
Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow
by Zacks Equity Research
Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.
Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.
Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.
Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.
Charles River (CRL) Launches Animal-Free Endotoxin Test
by Zacks Equity Research
Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.
ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries
by Zacks Equity Research
ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.
Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment
by Zacks Equity Research
Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.
Bruker (BRKR) to Advance in Lab Automation With New Buyout
by Zacks Equity Research
This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
by Zacks Equity Research
AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.
BD (BDX) Collaborates With Hamilton to Benefit Researchers
by Zacks Equity Research
Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?
by Zacks Equity Research
Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.